Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation
Cardiovascular Research · 31.07.2024 · 120 (9) · 1011-1023
DOI: 10.1093/cvr/cvae094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 22.05.2024. Verfasst von Nikoleta Pavlaki und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany. Hauptthemen laut MEDLINE: Cyclic AMP, Heart Failure, Genetic Therapy, Cyclic Nucleotide Phosphodiesterases, Type 2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: ERA-CVD, European Union, German Aerospace Center.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Gene therapy with cardiac phosphodiesterases (PDEs), such as phosphodiesterase 4B (PDE4B), has recently been described to effectively prevent heart failure (HF) in mice. However, exact molecular mechanisms of its beneficial effects, apart from general lowering of cardiomyocyte cyclic adenosine monophosphate (cAMP) levels, have not been elucidated. Here, we studied whether gene therapy with two types of PDEs, namely PDE2A and PDE4B, can prevent pressure-overload-induced HF in mice by acting on and restoring altered cAMP compartmentation in distinct subcellular microdomains. Methods and results HF was induced by transverse aortic constriction followed by tail-vein injection of adeno-associated-virus type 9 vectors to overexpress PDE2A3, PDE4B3, or luciferase for 8 weeks. Heart morphology and function was assessed by echocardiography and histology which showed that PDE2A and especially PDE4B gene therapy could attenuate cardiac hypertrophy, fibrosis, and decline of contractile function. Live cell imaging using targeted cAMP biosensors showed that PDE overexpression restored altered cAMP compartmentation in microdomains associated with ryanodine receptor type 2 (RyR2) and caveolin-rich plasma membrane. This was accompanied by ameliorated caveolin-3 decline after PDE2A3 overexpression, reduced RyR2 phosphorylation in PDE4B3 overexpressing hearts, and antiarrhythmic effects of both PDEs measured under isoproterenol stimulation in single cells. Strong association of overexpressed PDE4B but not PDE2A with RyR2 microdomain could prevent calcium leak and arrhythmias in human-induced pluripotent stem-derived cardiomyocytes with the A2254V mutation in RyR2 causing catecholaminergic polymorphic ventricular tachycardia.
Conclusion
Our data indicate that gene therapy with phosphodiesterases can prevent HF including associated cardiac remodelling and arrhythmias by restoring altered cAMP compartmentation in functionally relevant subcellular microdomains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany.
- DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Martinistr. 52, D-20246 Hamburg, Germany.
- Institute of Pharmacology and Toxicology, Technical University of Dresden, Dresden, Germany.
- Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany.
- Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
ORCID-Profile: Nikoleta Pavlaki, Alessandra Ghigo, Emilio Hirsch, Kaomei Guan, Viacheslav O Nikolaev
Förderung
- ERA-CVD
- European Union
- German Aerospace Center
Zitieren
APA
Pavlaki, N., Froese, A., Li, W., De Jong, K. A., Geertz, B., Subramanian, H., Mohagaonkar, S., Luo, X., Schubert, M., Wiegmann, R., Margaria, J. P., Ghigo, A., Kämmerer, S., Hirsch, E., El-Armouche, A., Guan, K., & Nikolaev, V. O. (2024). Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation. Cardiovascular Research, 120(9), 1011-1023. https://doi.org/10.1093/cvr/cvae094
Vancouver
Pavlaki N, Froese A, Li W, De Jong KA, Geertz B, Subramanian H, et al. Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation. Cardiovascular Research. 2024;120(9):1011-1023. doi:10.1093/cvr/cvae094
BibTeX
@article{Pavlaki2024,
author = {Pavlaki, Nikoleta and Froese, Alexander and Li, Wener and De Jong, Kirstie A and Geertz, Birgit and Subramanian, Hariharan and Mohagaonkar, Sanika and Luo, Xiaojing and Schubert, Mario and Wiegmann, Robert and Margaria, Jean Piero and Ghigo, Alessandra and Kämmerer, Susanne and Hirsch, Emilio and El-Armouche, Ali and Guan, Kaomei and Nikolaev, Viacheslav O},
title = {Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation},
journal = {Cardiovascular Research},
year = {2024},
volume = {120},
number = {9},
pages = {1011--1023},
doi = {10.1093/cvr/cvae094}
}
EUVIMED